MedTrace Logo

Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis

NCT06766461 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 980

Last updated 2025-01-09

No results posted yet for this study

Summary

The aim of this study is to investigate if an initial short double dose of beta-lactam antibiotics will reduce mortality in critically ill patients with sepsis.

Conditions

  • Sepsis - to Reduce Mortality in the Intensive Care Unit
  • Sepsis
  • Septic Shock

Interventions

DRUG

Double dosing of beta-lactam antibiotic

This arm will receive double dosing of beta-lactam antibiotics for the first 48 hours after inclusion.

Sponsors & Collaborators

  • Maasstad Hospital

    collaborator OTHER

  • Albert Schweitzer Hospital

    collaborator OTHER

  • Erasmus Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-03
Primary Completion
2026-12-01
Completion
2027-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06766461 on ClinicalTrials.gov